Prostate Cancer News

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of prostate cancer treatment and survivorship.

Share

Prostate Cancer News


Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (March 18, 2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a... Continue Reading

Zytiga Prolongs Time to Pain Progression (January 15, 2014)

The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone in chemotherapy-naive... Continue Reading

Oncotype DX Prostate Cancer Test Is Reliable Even in Small Samples (January 9, 2014)

The results of an analytical validation study demonstrate that the Oncotype DX® prostate cancer test is a reliable assay, even with very limited RNA inputs, which enables successful performance using... Continue Reading

Marriage May Have a Protective Effect for Cancer Patients (December 17, 2013)

Social support may have a significant impact on cancer detection, treatment, and survival, according to the results of a study published in the Journal of Clinical Oncology. The study showed that married... Continue Reading

Long-Term Hormone Therapy Offers No Benefit in Intermediate-Risk Prostate Cancer (November 13, 2013)

Long-term hormone therapy after radiation treatment for intermediate-risk prostate cancer does not improve disease-specific or overall survival, according to the results of a study presented at the annual... Continue Reading

Xofigo Improves Bone and Pain in Prostate Cancer (October 14, 2013)

Patients with hormone-refractory prostate cancer and bone metastases had significant improvement in skeletal- and pain-related outcomes when treated with Xofigo® (radium-223), according to the results... Continue Reading

Summary News on Melanoma, Breast, Cervical, Ovarian, Prostate and Thyroid Cancer from Amer Soc Clinical Oncology Annual Meeting (October 1, 2013)

By Kari Bohlke, ScD Annual meeting brings together cancer experts from around the world. For thousands of oncology professionals and cancer researchers from around the world, the Annual Meeting of the... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact,... Continue Reading

More Prostate Cancer News

Latest Prostate Cancer News By Stage


Screening and Prevention

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)

Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

Prostate Screening Not Recommended for Older Men (June 1, 2012)

The U.S. Preventive Services Task Force (USPSTF) recently drafted a grade D recommendation against prostate-specific antigen (PSA) screening for prostate cancer; however, it is unclear how this will affect screening practices since their previous recommendation... Continue Reading

More Screening and Prevention

Early Stage I-II (A-B)

Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (March 18, 2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate cancer. These results were published in the New... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Oncotype DX Prostate Cancer Test Is Reliable Even in Small Samples (January 9, 2014)

The results of an analytical validation study demonstrate that the Oncotype DX® prostate cancer test is a reliable assay, even with very limited RNA inputs, which enables successful performance using small amounts of cancer tissue typically available... Continue Reading

Long-Term Hormone Therapy Offers No Benefit in Intermediate-Risk Prostate Cancer (November 13, 2013)

Long-term hormone therapy after radiation treatment for intermediate-risk prostate cancer does not improve disease-specific or overall survival, according to the results of a study presented at the annual meeting of the American Society of Radiation Oncology. Hormone... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

More Early Stage I-II (A-B)

Locally Advanced Stage III (C)

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery (June 18, 2013)

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have issued a joint guideline regarding the use of radiation therapy after prostatectomy. It marks the first time the two medical organizations—most responsible... Continue Reading

Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)

A new genomic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading

Early Radiation Improves Prostate Cancer Survival (March 7, 2013)

Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according to the results of a study presented at the Genitourinary... Continue Reading

More Locally Advanced Stage III (C)

Metastatic Stage IV (D)

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers... Continue Reading

Zytiga Prolongs Time to Pain Progression (January 15, 2014)

The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone in chemotherapy-naive men with metastatic castration-resistant... Continue Reading

Xofigo Improves Bone and Pain in Prostate Cancer (October 14, 2013)

Patients with hormone-refractory prostate cancer and bone metastases had significant improvement in skeletal- and pain-related outcomes when treated with Xofigo® (radium-223), according to the results of a study presented at the annual meeting of the... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

More Metastatic Stage IV (D)

Refactory/Recurrent

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers... Continue Reading

Zytiga Prolongs Time to Pain Progression (January 15, 2014)

The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone in chemotherapy-naive men with metastatic castration-resistant... Continue Reading

Xofigo Improves Bone and Pain in Prostate Cancer (October 14, 2013)

Patients with hormone-refractory prostate cancer and bone metastases had significant improvement in skeletal- and pain-related outcomes when treated with Xofigo® (radium-223), according to the results of a study presented at the annual meeting of the... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

<More Refactory/Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS